Fischer Medical Ventures Limited has scheduled a meeting with analysts and investors on September 7, 2026. The company disclosed the agenda via an exchange filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting details

The engagement is designed to update stakeholders on the company's strategic direction. Fischer Medical Ventures described itself as building the world's largest Healthcare AI Solutions Platform, focusing on AI-enabled medical imaging, population-scale screening, and hospital digitization.

Strategic ecosystem

The presentation highlighted an integrated ecosystem comprising three operating brands:

• Time Medical: Provides the technology foundation with advanced MRI and diagnostic equipment.
• FMV: Acts as the commercialization and capital vehicle, integrating diagnostics, AI, and biologics.
• FlynnCare: Develops AI healthcare applications, including the MIDAS screening ecosystem.

This structure aims to converge technology, commercialization, and AI applications into a single integrated healthcare innovation engine.

Product portfolio

The company outlined its key product verticals:

Medical Imaging

Time Medical offers a full-spectrum MRI portfolio ranging from 0.35T open systems (PICA, AURA) to 7.0T ultra-high field research platforms (Nova 7T). The range includes helium-free magnets and closed-bore systems like the MICA and QUIN series. The company also listed CT imaging solutions (Clarion series) and portable X-ray devices as part of its diagnostic offerings.

AI & Digital Health

FlynnCare's MIDAS platform enables multi-disciplinary early disease detection across eye, oral, mental, and cardiovascular health. The LIVE Dx platform supports population-scale screening with tele-health integration. Additionally, the Clinics 2.0 platform provides EHR, HIS, and practice management solutions.

Biologics & Other Ventures

Nanyang Biologics focuses on AI-driven drug discovery using NVIDIA and HPE infrastructure, with partnerships involving Johnson & Johnson Innovation JLABS. The company also mentioned SpinCare regenerative skin technology and Obelab brain imaging platforms.

Fischer Medical Ventures Limited appointed David Yeow as an additional independent director effective September 3, 2026. The company also announced September 22, 2026, as the record date for its 33rd Annual General Meeting and dividend entitlement.

The Board of Directors approved these governance updates in a meeting held on September 3, 2026. The appointment was made pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The record date intimation was issued under Regulation 42 of the same regulations.

Director Appointment Details

Mr. Yeow joins the board for a first term of five consecutive years, subject to shareholder approval. He is not liable to retire by rotation. The Singapore-based engineer brings over three decades of experience in manufacturing, quality systems, and global supply chain management.

He holds a Diplôme d'Ingénieur in Electronic Engineering from the École Nationale Supérieure d'Électronique et de Radioélectricité de Bordeaux and is a GE-certified Six Sigma Blackbelt. Previously, he held senior leadership roles at GE Plastics, Lanxess, and NTUitive. He currently serves as Principal at Hunniwell Lake Ventures, a medical device venture capital firm.

Audit Committee Reconstitution

Following the new appointment, the Board reconstituted the Audit Committee. The committee now comprises seven members, including four independent directors, one executive director, and one whole-time director.

AGM Scheduling and Record Dates

The company will hold its 33rd Annual General Meeting on Tuesday, September 29, 2026, at 11:00 am through video conferencing or other audio-visual means. M/s Nuren Lodaya & Associates Practising Company Secretary has been appointed as the scrutinizer for the e-voting process.

The Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 29, 2026, inclusive. This closure facilitates the AGM proceedings.

Tuesday, September 22, 2026, is the cut-off date for determining voting rights for e-voting on resolutions listed in the AGM notice and for dividend entitlement. The cut-off date for determining shareholders entitled to receive the dispatch of the AGM notice was September 4, 2026.